Analyst firms · Citigroup · NBIX
Citigroup NBIX price target and rating history
Neurocrine Biosciences Inc. (NBIX) · Health Care
Citigroup rates Neurocrine Biosciences Inc. (NBIX) Buy with a $175 price target, as of its latest action on Oct 21, 2025. It has published 3 rating actions on NBIX since December 2021, including 0 upgrades and 0 downgrades. Across 5 firms with a NBIX price target in the last 12 months, the median target is $207.
- Current rating
- Buy
- Price target
- $175
- Median target, all firms
- $207
- Actions on NBIX
- 3
Citigroup price target on NBIX
Every Citigroup rating on NBIX
- Oct 21, 2025
- Dec 13, 2023
- Dec 8, 2021
How other firms rate NBIX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Guggenheim | Buy | $207 | Oct 6, 2026 |
| Goldman Sachs | Buy | $213 | Jun 2, 2026 |
| Bernstein | Outperform | $221 | May 22, 2026 |
| Wolfe Research | Outperform | $160 | Feb 24, 2026 |
| Morgan Stanley | Equal-Weight | $175 | Jan 8, 2026 |
Questions about Citigroup and NBIX
- What is Citigroup's price target for NBIX?
- Citigroup's latest stated price target for Neurocrine Biosciences Inc. (NBIX) is $175, from its action on Oct 21, 2025.
- What is Citigroup's rating on NBIX?
- Citigroup rates NBIX Buy, a bullish rating, as of Oct 21, 2025.
- When did Citigroup last change its view on NBIX?
- On Oct 21, 2025, Citigroup starts coverage at Buy, price target $175.
- How does Citigroup's NBIX target compare with other analysts?
- Across 5 firms with a NBIX price target in the last 12 months, the median target is $207.
More NBIX rating histories
All Citigroup ratingsNBIX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.